glp-1 drugs and dementia Drug Fails to Quell Alzheimer's in Novo Nordisk Trials Comparing Ozempic, Wegovy and Other
Description
The approval was expanded in October 2025 to include cardiovascular risk reduction in people with Type 2 diabetes
EX, exenatide
These medications also increase the uptake of glucose by muscle tissue, decrease glucose release by the liver, and increase satiety at the level of the hypothalamus
Obesity is a well-established major risk factor for metabolic disorders including diabetes
Hence, they are not recommended as initial therapy for treatment of T2D
Diabetes, 63 ,
